[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201790380A1 - Ингибиторы mk2 и их применения - Google Patents

Ингибиторы mk2 и их применения

Info

Publication number
EA201790380A1
EA201790380A1 EA201790380A EA201790380A EA201790380A1 EA 201790380 A1 EA201790380 A1 EA 201790380A1 EA 201790380 A EA201790380 A EA 201790380A EA 201790380 A EA201790380 A EA 201790380A EA 201790380 A1 EA201790380 A1 EA 201790380A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
applications
compositions
methods
present
Prior art date
Application number
EA201790380A
Other languages
English (en)
Other versions
EA037299B1 (ru
Inventor
Мэттью Дэвид Александр
Клаудио Чуаки
Джон Малона
Джозеф Джон Макдоналд
Айк Ни
Децян Ню
Расселл К. Петтер
Джасвиндер Сингх
Читтари Пабба
Original Assignee
Селджен Кар Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селджен Кар Ллс filed Critical Селджен Кар Ллс
Publication of EA201790380A1 publication Critical patent/EA201790380A1/ru
Publication of EA037299B1 publication Critical patent/EA037299B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

В настоящем изобретении предложены соединения, их композиции и способы их применения.
EA201790380A 2014-09-17 2015-09-16 Ингибиторы mk2 и их применения EA037299B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US201562199927P 2015-07-31 2015-07-31
PCT/US2015/050495 WO2016044463A2 (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
EA201790380A1 true EA201790380A1 (ru) 2017-08-31
EA037299B1 EA037299B1 (ru) 2021-03-05

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790380A EA037299B1 (ru) 2014-09-17 2015-09-16 Ингибиторы mk2 и их применения

Country Status (29)

Country Link
US (5) US9458175B2 (ru)
EP (2) EP3193611B1 (ru)
JP (3) JP6556225B2 (ru)
KR (1) KR102457848B1 (ru)
CN (1) CN106998692B (ru)
AU (1) AU2015317741B2 (ru)
BR (1) BR112017005266B1 (ru)
CA (1) CA2961607C (ru)
CL (1) CL2017000576A1 (ru)
CO (1) CO2017003279A2 (ru)
CY (1) CY1124215T1 (ru)
DK (1) DK3193611T3 (ru)
EA (1) EA037299B1 (ru)
EC (1) ECSP17023281A (ru)
ES (1) ES2874561T3 (ru)
HR (1) HRP20210529T1 (ru)
HU (1) HUE054347T2 (ru)
IL (1) IL251051B (ru)
LT (1) LT3193611T (ru)
MA (1) MA40534B1 (ru)
MX (2) MX2017003359A (ru)
PL (1) PL3193611T3 (ru)
PT (1) PT3193611T (ru)
RS (1) RS62017B1 (ru)
SA (1) SA517381115B1 (ru)
SG (2) SG11201701861RA (ru)
SI (1) SI3193611T1 (ru)
TW (1) TWI744217B (ru)
WO (1) WO2016044463A2 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150133172A (ko) 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
MA40534B1 (fr) 2014-09-17 2021-04-30 Celgene Car Llc Inhibiteurs de mk2 et leurs utilisations
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
EP3596085A4 (en) * 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
CN110678471B (zh) * 2017-03-16 2022-09-13 西建卡尔有限责任公司 Mk2抑制剂及其合成和中间体
MX2019010643A (es) 2017-03-16 2019-10-17 Celgene Car Llc Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
US11098057B2 (en) * 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
EP3596083A4 (en) * 2017-03-16 2020-12-02 Celgene CAR LLC USEFUL HETERARYL COMPOUNDS AS MK2 INHIBITORS
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
JP2022533368A (ja) * 2019-05-17 2022-07-22 セルジーン シーエーアール エルエルシー Ｍｋ２媒介性障害の治療方法
KR20220154094A (ko) * 2020-02-14 2022-11-21 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ulk1/2 억제제를 이용한 단일 및 병용 요법
EP4114411A4 (en) * 2020-03-02 2024-04-24 Washington University COMPOSITIONS AND METHODS FOR THE TREATMENT OF PANCREATIC CANCER
KR20230044446A (ko) * 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
CN117940433A (zh) * 2021-08-27 2024-04-26 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
AU2023207395A1 (en) 2022-01-14 2024-07-11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
US20240190890A1 (en) * 2022-10-27 2024-06-13 Bristol-Myers Squibb Company Mk2 inhibitors and uses thereof
WO2024167950A1 (en) * 2023-02-07 2024-08-15 Celgene Corporation Compounds and compositions useful as degraders of mk2 kinase

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2004058176A2 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Acyclic pyrazole compounds
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
WO2006084186A2 (en) 2005-02-04 2006-08-10 Senomyx, Inc. Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
PE20090480A1 (es) 2007-07-16 2009-05-24 Novartis Ag Derivados de lactama tetraciclicos
CN101910151A (zh) 2007-10-22 2010-12-08 先灵公司 双环杂环衍生物及其作为gpr119活性调节剂的用途
JP2011526299A (ja) 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
JP6396216B2 (ja) 2012-02-22 2018-09-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 液晶媒体
US9187453B2 (en) * 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
US20150269216A1 (en) * 2012-09-24 2015-09-24 Claremont Speede Mobile sender controlled data access and data deletion method and system
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
KR20150133172A (ko) 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
WO2016032882A1 (en) 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
MA40534B1 (fr) 2014-09-17 2021-04-30 Celgene Car Llc Inhibiteurs de mk2 et leurs utilisations
BR112017014737A2 (pt) 2015-01-08 2018-01-16 Moerae Matrix Inc formulação de peptídeos inibidores de mk2
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
EP3596083A4 (en) 2017-03-16 2020-12-02 Celgene CAR LLC USEFUL HETERARYL COMPOUNDS AS MK2 INHIBITORS
MX2019010643A (es) 2017-03-16 2019-10-17 Celgene Car Llc Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
CN110678471B (zh) 2017-03-16 2022-09-13 西建卡尔有限责任公司 Mk2抑制剂及其合成和中间体
JP2022533368A (ja) 2019-05-17 2022-07-22 セルジーン シーエーアール エルエルシー Ｍｋ２媒介性障害の治療方法
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법

Also Published As

Publication number Publication date
US9458175B2 (en) 2016-10-04
US10577380B2 (en) 2020-03-03
BR112017005266B1 (pt) 2022-11-01
MA40534B1 (fr) 2021-04-30
JP2017529367A (ja) 2017-10-05
HUE054347T2 (hu) 2021-08-30
SA517381115B1 (ar) 2021-03-09
EP3912981A1 (en) 2021-11-24
IL251051A0 (en) 2017-04-30
SG10201902326XA (en) 2019-04-29
MX2017003359A (es) 2017-11-22
JP6556225B2 (ja) 2019-08-07
AU2015317741A1 (en) 2017-04-20
US20160075720A1 (en) 2016-03-17
PL3193611T3 (pl) 2021-10-04
CA2961607C (en) 2023-03-28
EP3193611A4 (en) 2018-02-28
PT3193611T (pt) 2021-05-28
DK3193611T3 (da) 2021-05-10
MX2020005213A (es) 2020-08-20
AU2015317741B2 (en) 2020-01-16
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
US20210053984A1 (en) 2021-02-25
TW201617351A (zh) 2016-05-16
IL251051B (en) 2019-11-28
WO2016044463A3 (en) 2016-09-01
CN106998692A (zh) 2017-08-01
MA40534A (fr) 2016-03-24
LT3193611T (lt) 2021-08-25
SG11201701861RA (en) 2017-04-27
US11584757B2 (en) 2023-02-21
KR102457848B1 (ko) 2022-10-25
BR112017005266A2 (pt) 2017-12-12
CL2017000576A1 (es) 2017-12-01
JP2022078315A (ja) 2022-05-24
US20170114073A1 (en) 2017-04-27
RS62017B1 (sr) 2021-07-30
US10253040B1 (en) 2019-04-09
EP3193611A2 (en) 2017-07-26
US20190375762A1 (en) 2019-12-12
CA2961607A1 (en) 2016-03-24
JP7375072B2 (ja) 2023-11-07
ECSP17023281A (es) 2017-06-30
KR20170063734A (ko) 2017-06-08
CO2017003279A2 (es) 2017-09-29
SI3193611T1 (sl) 2021-08-31
EA037299B1 (ru) 2021-03-05
TWI744217B (zh) 2021-11-01
CY1124215T1 (el) 2022-05-27
US9790235B2 (en) 2017-10-17
NZ730603A (en) 2024-02-23
JP2019194236A (ja) 2019-11-07
EP3193611B1 (en) 2021-03-24
WO2016044463A2 (en) 2016-03-24
CN106998692B (zh) 2020-09-08

Similar Documents

Publication Publication Date Title
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201591137A1 (ru) Ингибиторы mk2 и их применения
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
BR112016018521A2 (pt) composição, e, kit.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
EA201790173A1 (ru) Антитела, связывающие axl
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA202092926A3 (ru) Лиофилизированные составы, содержащие фактор ix
PH12017501864A1 (en) Compositions and methods for treating autism
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM